Barclays’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-11,755
| Closed | -$46K | – | 4456 |
|
|
2023
Q3 | $46K | Sell |
11,755
-81,438
| -87% | -$319K | ﹤0.01% | 3637 |
|
|
2023
Q2 | $303K | Buy |
93,193
+92,649
| +17,031% | +$301K | ﹤0.01% | 2885 |
|
|
2023
Q1 | $2K | Sell |
544
-588
| -52% | -$2.16K | ﹤0.01% | 4236 |
|
|
2022
Q4 | $36K | Buy |
1,132
+982
| +655% | +$31.2K | ﹤0.01% | 3882 |
|
|
2022
Q3 | $6K | Buy |
+150
| New | +$6K | ﹤0.01% | 4356 |
|
|
2022
Q2 | – | Sell |
-247
| Closed | -$17K | – | 5035 |
|
|
2022
Q1 | $17K | Sell |
247
-1,596
| -87% | -$110K | ﹤0.01% | 4378 |
|
|
2021
Q4 | $224K | Buy |
1,843
+1,222
| +197% | +$149K | ﹤0.01% | 2798 |
|
|
2021
Q3 | $87K | Buy |
621
+429
| +223% | +$60.1K | ﹤0.01% | 3270 |
|
|
2021
Q2 | $53K | Sell |
192
-771
| -80% | -$213K | ﹤0.01% | 3371 |
|
|
2021
Q1 | $206K | Buy |
963
+640
| +198% | +$137K | ﹤0.01% | 3112 |
|
|
2020
Q4 | $78K | Sell |
323
-129
| -29% | -$31.2K | ﹤0.01% | 3048 |
|
|
2020
Q3 | $48K | Buy |
452
+60
| +15% | +$6.37K | ﹤0.01% | 3304 |
|
|
2020
Q2 | $38K | Buy |
392
+165
| +73% | +$16K | ﹤0.01% | 3469 |
|
|
2020
Q1 | $17K | Sell |
227
-466
| -67% | -$34.9K | ﹤0.01% | 3415 |
|
|
2019
Q4 | $56K | Buy |
693
+352
| +103% | +$28.4K | ﹤0.01% | 3569 |
|
|
2019
Q3 | $41K | Sell |
341
-109
| -24% | -$13.1K | ﹤0.01% | 3731 |
|
|
2019
Q2 | $81K | Buy |
450
+255
| +131% | +$45.9K | ﹤0.01% | 3688 |
|
|
2019
Q1 | $31K | Buy |
+195
| New | +$31K | ﹤0.01% | 3813 |
|
|
2018
Q4 | – | Sell |
-101
| Closed | -$24K | – | 4495 |
|
|
2018
Q3 | $24K | Buy |
101
+81
| +405% | +$19.2K | ﹤0.01% | 3903 |
|
|
2018
Q2 | $5K | Buy |
+20
| New | +$5K | ﹤0.01% | 4006 |
|